Atara Biotherapeutics, Inc. (ATRA)
ATRA moved a median of -0.27% 30 minutes after news, and -0.10% by the close. How ATRA actually reacts to news — the realized, point-in-time move the market made, measured across 813 labeled events over the last three years with zero look-ahead.
ATRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 742 |
| 30-min | -0.27% | 45% | 802 |
| 60-min | +0.20% | 52% | 811 |
| to close | -0.10% | 47% | 807 |
| Middle 50% of ATRA reactions | -1.82% to +1.40% |
|---|---|
| Median reaction (30-min) | -0.27% |
| Measured reactions | 813 |
Half of all Atara Biotherapeutics, Inc. news events land between -1.82% and +1.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ATRA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | -0.38% | 35% | +1.73% |
| Analyst downgrades | 18 | -1.97% | 28% | -23.77% |
| Rating reiterations | 24 | +0.72% | 67% | +2.58% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ATRA ranks against every other measured name →
That’s how ATRA usually reacts — get an email when it moves on news →Email me when ATRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ATRA's baseline. Nothing else.
Recent ATRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration | Press release | Business Wire | -0.75% | +2.91% | |
| Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | +1.47% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation Into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.85% | -0.42% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Connect | Press release | ACCESS Newswire | — | +3.40% | |
| Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.99% | +1.72% | |
| Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration | Press release | Business Wire | -0.49% | +5.20% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | — | -0.58% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | — | -5.10% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | -3.60% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.74% | +2.72% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.56% | -5.10% | |
| Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | +2.03% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.87% | -2.09% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | -0.75% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | -1.15% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | — | +0.00% | |
| Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress | Press release | Business Wire | -3.36% | +2.04% | |
| Form 10-Q Atara Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.36% | +2.04% | |
| Form 8-K Atara Biotherapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -3.36% | +2.04% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.13% | +4.97% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.78% | +3.83% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | — | +3.66% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | +2.53% | |
| Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -3.54% | -9.78% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | -1.35% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.30% | -6.77% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | — | +3.99% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.33% | +5.38% | |
| Form 8-K Atara Biotherapeutics, For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | +5.38% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.09% | -8.26% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.50% | +6.85% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.25% | +1.56% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.33% | -5.14% | |
| Atara Biotherapeutics Announces Changes to Its Board of Directors | Press release | Business Wire | -2.33% | -5.14% | |
| Form 8-K Atara Biotherapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -5.14% | |
| Form S-8 Atara Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | -2.33% | -5.14% | |
| Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.51% | -1.41% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.20% | +1.68% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -3.13% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +1.53% | +7.44% | |
| Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress | Press release | Business Wire | +9.00% | +13.67% | |
| Form 10-Q Atara Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +9.00% | +13.67% | |
| Form 8-K Atara Biotherapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +9.00% | +13.67% | |
| Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel | Press release | Business Wire | -9.47% | +26.18% | |
| Form 8-K Atara Biotherapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -9.47% | +26.18% | |
| Form 8-K Atara Biotherapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.41% | |
| Form DEF 14A Atara Biotherapeutics, For: Apr 24 | SEC filing · Form DEF | SEC EDGAR | -0.20% | +1.01% | |
| Form DEFA14A Atara Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.20% | +1.01% | |
| Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRA | Press release | Business Wire | +2.46% | -3.48% | |
| Form EFFECT Atara Biotherapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +2.46% | -3.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ATRA section they belong to.
Where else ATRA is measured.
ATRA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CYTRX CORP (CYTR) | 821 | -0.00% | 43% |
| Sinovac Biotech, Ltd. - Ordinary Shares (Antigua/Barbudo) (SVA) | 814 | 0.00% | 46% |
| Ionis Pharmaceuticals, Inc. (IONS) | 811 | +0.02% | 52% |
| Applied Genetic Technologies Corporation (AGTC) | 805 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Atara Biotherapeutics, Inc.'s median reaction calculated?
Every labeled ATRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 813 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of ATRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ATRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.